Genes discriminating between breast cancers responsive or resistant to the aromatase inhibitor, letrozole

European journal of Clinical and Medical Oncology

Volumn 2, Issue 2, 2010, Pages

  Miller, William R ^a,d   Krause, Andreas ^b   Larionov, Alexey ^a,e   Evans, Dean B ^c   Anderson, Thomas J ^a   Michael Dixon, J ^a,e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NONE   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast cancer; Gene expression; Letrozole

Indexed keywords

AROMATASE INHIBITOR; LETROZOLE; RIBOSOME PROTEIN;

ADULT; AGED; BIOINFORMATICS; BREAST CANCER; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; REVIEW; RIBOSOME; TUMOR BIOPSY;

EID: 77956296913     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Carpenter R, Miller WR. Role of aromatase inhibitors in breast cancer. Br J Cancer. 2005;93(Suppl 1):S1-5.
2. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003;21:2597-2599.
3. Eiermann W, Paepke S, Appfelstaedt J, et al. Letrozole Neo-Adjuvant Breast Cancer Study Group 2001. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527-1532.
4. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808-3816.
5. Miller WR, Larionov A, Renshaw L, et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol. 2009;27:1382-1387.
6. Breiman L. ''Random Forests''. Machine Learning. 2001;45(1):5-32.
7. Tusher V, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;8:5116-5121.
8. Schwender H, Krause A, Ickstadt K. Identifying interesting genes with siggenes. The Newsletter of the R Project. 2006;6:45-50.
9. Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM, Miller WR. MIB- 1 assessments in breast cancers. Breast. 2002;11:252-256.
10. Scherer A, Krause A, Walker JR, et al. An optimized protocol for linear RNA amplification and its application to RNA expression profiling of human renal biopsies. BioTechniques. 2003;34:546-556.
11. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucl Acids Res. 2003; 31:e15.
12. Zheng Q, Wang XJ. GOEAST: a web-based software toolkit for Gene Ontology enrichment analysis. Nucl Acids Res. 2008;36(Web Server issue): W358-363.
13. Björklund M, Taipale M, Varjosalo M, Saharinen J, Lahdenperä J, Taipale J. Identification of pathways regulating cell size and cell-cycle progression by RNAi Nature. 2006;439:1009-1013.
14. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nature Rev Cancer. 2003;3:179-192.
15. Lindström MS. Emerging functions of ribosomal proteins in genespecific transcription and translation. Biochem Biophys Res Commun. 2009; 379:167-170.
16. Dai MS, Lu H. Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem. 2008;105:670-677.
17. Musgrove EA, Sergio CM, Loi S, et al. Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS ONE. 2008;3: e2987.
18. Lai MD, Xu J. Ribosomal proteins and colorectal cancer. Curr Genomics. 2007;8:43-49.
19. Montanaro L, Treré D, Derenzini M. Nucleolus, ribosomes, and cancer. Am J Pathol. 2008;173:301-310.
20. Chang TW, Chen CC, Chen KY, Su JH, Chang JH, Chang MC. Ribosomal phosphoprotein P0 interacts with GCIP and overexpression of P0 is associated with cellular proliferation in breast and liver carcinoma cells. Oncogene. 2008;27:332-338.
21. Desmedt C, Azambuja E, Di Leo A, et al. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-monotherapy in estrogen-receptor (ER) negative breast cancer (BC) patients. San Antonio Breast Cancer Symposium, 2006, poster 3022.